UBS Group Analysts Give Celgene (CELG) a $94.00 Price Target

UBS Group set a $94.00 price target on Celgene (NASDAQ:CELG) in a research report released on Saturday, www.stocktargetadvisor.com reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on the company. Zacks Investment Research downgraded Celgene from a buy rating to a hold rating in a research note on Wednesday, September 26th. JPMorgan Chase & Co. reissued a buy rating on shares of Celgene in a report on Thursday, October 11th. Mizuho reissued a buy rating and issued a $129.00 price target on shares of Celgene in a report on Tuesday, July 31st. Cantor Fitzgerald began coverage on Celgene in a report on Monday, October 1st. They issued an overweight rating and a $100.00 price target on the stock. Finally, BidaskClub cut Celgene from a buy rating to a hold rating in a report on Thursday, September 13th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Celgene has a consensus rating of Buy and a consensus target price of $117.91.

Shares of NASDAQ:CELG opened at $72.34 on Friday. The company has a market cap of $50.66 billion, a P/E ratio of 10.58, a P/E/G ratio of 0.43 and a beta of 1.30. The company has a quick ratio of 1.99, a current ratio of 2.13 and a debt-to-equity ratio of 4.06. Celgene has a 12-month low of $70.09 and a 12-month high of $110.81.



Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.02 by $0.27. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. On average, sell-side analysts expect that Celgene will post 7.76 earnings per share for the current year.

In other news, Director Ernest Mario sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $92.32, for a total transaction of $1,107,840.00. Following the sale, the director now directly owns 44,413 shares of the company’s stock, valued at approximately $4,100,208.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John H. Weiland acquired 5,575 shares of the firm’s stock in a transaction dated Tuesday, August 7th. The shares were purchased at an average cost of $89.73 per share, for a total transaction of $500,244.75. The disclosure for this purchase can be found here. 0.39% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of CELG. WINTON GROUP Ltd purchased a new stake in shares of Celgene during the 1st quarter worth approximately $308,000. Cacti Asset Management LLC purchased a new stake in shares of Celgene during the 2nd quarter worth approximately $1,744,000. Neville Rodie & Shaw Inc. purchased a new stake in shares of Celgene during the 2nd quarter worth approximately $9,179,000. New England Research & Management Inc. increased its position in shares of Celgene by 5.1% during the 2nd quarter. New England Research & Management Inc. now owns 18,676 shares of the biopharmaceutical company’s stock valued at $1,483,000 after purchasing an additional 900 shares during the last quarter. Finally, Verde Servicos Internacionais S.A. bought a new position in shares of Celgene during the 2nd quarter valued at approximately $1,403,000. 72.98% of the stock is currently owned by institutional investors and hedge funds.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: How to Invest in Growth Stocks

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply